Nattokinase recommended by JNKA is passing the following safety tests.

1.  Various Safety Datas (in vitro and in vivo)
  ・Single oral administration toxicity test
  ・28-day repeated oral dose toxicity study
  ・90-day repeated oral dose toxicity study
  ・Reverse mutation test
  ・Chromosome aberration test
  ・Pathogenicity test

2.  Human Safety Study
 ・Oral Nattokinase supplementation + low molecular weight heparin + anti-platelet aggregation drug combination (in India)
 ・Double-blind, parallel-group study of Nattokinase supplementation (2000 FU/day) (in Japan)

3. use and control of non-GMO (including IP handling) and non-animal ingredients